17. Assessment of responsibilities after 3 months of stereotatic body radiation therapy in early-stage non-small cell lung cancer according to RECIST and PERCIST
Main Article Content
Abstract
The objective of this study was to evaluate the response after 3 months of stereotactic body radiation therapy (SBRT) in patients with stage I non-small cell lung cancer (NSCLC) with peripheral lung tumor according to RECIST 1.1 and PERCIST 1.0. This is a prospective and follow-up study of 32 patients with stage I NSCLC (T1-T2aN0M0) with peripheral lung tumors, who received SBRT and evaluated after 3 months from January 2015 to March 2022. Response to treatment after 3 months was assessed according to RECIST 1.1 and PERCIST 1.0. The results showed a change in the percentage of T1a and T1b stages on chest CT by 25% and 31.3%, respectively, compared with the corresponding rates on PET/CT of 18.8% and 37.5%. The difference was statistical significance with p < 0.01. According to RECIST 1.1, there was no complete response, 41.4% partial response, 37.9% stable disease, 20.7% progressive disease, objective response rate 41.4% and disease control rate 79.3%. According to PERCIST 1.0, 1 patient had a complete response, the other rates were 65.5%, 24.1%, 6.9%, 68.9% and 93%, respectively; the difference was statistical significance with p = 0.021. Conclusion: Using the PERCIST 1.0 criteria changes the ratio of treatment response statistically significantly compared with the RECIST 1.1 criteria. Especially, 13.8% of patients continued to enjoy the benefits of SBRT evaluating according to PERCIST 1.0.
Article Details
Keywords
early-stage non-small cell lung cancer, stereotactic body radiation therapy, RECIST 1.1, PERCIST 1.0
References
2. B. J. Schneider, M. E.Daly, E. B.Kennedy, et al. Stereotactic Body Radiation Therapy for early-stage non-small cell lung cancer: American society for clinical oncology endorsement of the American society for radiation oncology evidence-based guideline. J Clin Oncol. 2017;36:710-719.
3. A. Shinde, R. Li, J. Kim, et al. Stereotactic Body Radiation Therapy (SBRT) for early-stage lung cancer in the elderly. Seminars in Oncology. 2018;45:210-219.
4. P. Alcantara, B. C. Martínez, M. G. García-Esquinas, et al. Evaluation of tumor response after Stereotactic Body Radiation Therapy for lung cancer: Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography. Journal of Clinical and Translational Research. 2020;6(5):155-167.
5. Ikezoe J., Takashima S., Morimoto S., et al. CT appearance of acute radiation-induced injury in the lung. AJR Am J Roentgenol. 1988;150(4):765-770.
6. Dunlap N.E., Yang W., McIntosh A., et al. Computed tomography-based anatomic assessment overestimates local tumor recurrence in patients with mass like consolidation after stereotactic body radiotherapy for early-stage non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;84:1071-1077.
7. Hoopes D.J., Tann M., Fletcher J.W, et al. FDG-PET and Stereotactic Body Radiotherapy (SBRT) for stage I non-small-cell lung cancer. Lung Cancer. 2007;56:229-34.
8. Nagata Y., Hiraoka M., Shibata T., et al. Stereotactic Body Radiation Therapy for T1N0M0 non-small cell lung cancer first report for inoperable population of a Phase II trial by Japan Clinical Oncology Group (JCOG 0403). Int J Radiat Oncol Biol Phys. 2012;84(Suppl):S46-S46.
9. R. Timmerman, R. Paulus, J. Galvin, et al, Stereotactic Body Radiation Therapy for inoperable early-stage lung cancer. JAMA. 2010;303(11):1070-6.
10. Pia Bauman, Jan Nyman, Morten Hoyer, et al. Outcome in a prospective phage II trial of medically inoperable stage I non-small cell lung cancer patients treated with Stereotactic Body Radiation Therapy. J Clin Oncol. 2009;27:3290-3296.
11. Gregory M. M. V., Chen H., Anurag K. S., et al. NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase II study comparing 2 Stereotactic Body Radiation Therapy (SBRT) schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;93(4):757-764.
12. J.Vansteenkiste, L.Crino, J.Y.Douillard, et al. 2nd ESMO Consensus conferencer on lung cancer: early stage non-small cell lung cancer consensus ondiagnosis, treatment and follow-up. Annals of Oncology. 2014:00:1-13.
13. Katsunari M., Shinichi S., Nariyasu N., et al. Prognostic value of carcinoembryonic antigen and CYFRA21-1 in patients with pathological stage I non-small cell lung cancer. European Journal of Cardio-thoracic Surgery. 2007;32:435-439.
14. Funda A., Levent D., Evrim S. B., et al,. Measurements of tumor size using CT and PET compared to histopathological size in non-small cell lung cancer. Diagn Interv Radiol. 2013;19:271-278.
15. Sheikhbahaei S., Mena E., Yanamadala A., et al. The value of FDG PET/CT in treatment response assessment, follow up, and surveillance of lung cancer. Am J Roentgenol. 2017;208:420-33.
16. Nicholas J. Pastis Jr, Travis J. G., Nichole T. T., et al. Assessing the usefulness of 18F-fluorodeoxyglucose PET-CT scan after Stereotactic Body Radiotherapy for early-stage non-small cell lung cancer. CHEST. 2014;146(2):406-411.
17. C. Pierson, Taras G, Casey S, et al. Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy. Radiation Oncology. 2018;13:34.
18. M. Ding, W. Zollinger, R. Ebeling, et al. Using max standardized uptake value from positron emission tomography to assess tumor responses after lung stereotactic body radiotherapy for different prescriptions. Appl Clin Med Phys. 2018;19(6)226-233.